Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2003) 6 P35

Endocrine tumours and neoplasia

THE SENSITIVITY OF (super)123I-MIBG IN THE DETECTION OF HISTOLOGICALLY CONFIRMED CATECHOLAMINE-PRODUCING TUMOURS

M Ismail, R Foley, WM Drake, AB Grossman, PJ Jenkins, SL Chew, GM Besser, R Resnek, K Britton & JP Monson

183 views


Department of Endocrinology, Nuclear medicine and Radiology, St. Bartholomew's Hospital, Queen Mary University of London, London EC1A 7BE, UK.


THE SENSITIVITY OF 123I-MIBG IN THE DETECTION OF HISTOLOGICALLY CONFIRMED CATECHOLAMINE-PRODUCING TUMOURS.

M Ismail, R Foley, WM Drake, AB Grossman, PJ Jenkins, SL Chew, GM

Besser, R Reznek, K Britton, JP Monson

Departments of Endocrinology, Nuclear Medicine and Radiology, St

Bartholomew's Hospital (QMUL), London EC1A 7BE

Radionuclide imaging is widely used for the localization of

catecholamine-producing tumors. This is best performed with 123I-meta-iodo-

benzylguanidine (MIBG), a catecholamine (noradrenaline) analogue that utilises the amine precursor uptake mechanism and may thus be

incorporated into vesicles or neurosecretory granules in the cytoplasm. Gamma-camera images are then obtained using a low-energy collimator interfaced with a computer.

We describe a series of 31 consecutive patients presenting to our department

at St. Bartholomew's Hospital between January 1999 and April 2003 with a

diagnosis of a catecholamine-secreting tumour, elevation of urine

catecholamines and subsequent histological confirmation. 123I-MIBG

scanning was performed pre-operatively in all patients. Our series comprised

20 men (65%) and 11 women (35%); 26/31 of these tumors were primary

adrenal (84%), 3 of which were metastatic at the time of diagnosis

(11.5%); and five were extra-adrenal (16%). 123I-MIBG scanning detected 20/26 primary adrenal catecholamine-producing tumours and 3/5 extra-adrenal tumors giving a sensitivity of 77% and 60% respectively. In patients with metastatic adrenalphaeochromocytoma 123I-MIBG avidity was evident in 2 of the 3

cases.

The overall sensitivity of 123I-MIBG scanning was 74% compared with a

reported sensitivity of 80-90% in previously reported smaller series.

There was no relationship between the biochemical severity of the condition

and the presence or absence of 123I-MIBG avidity. Because our inclusion

criteria depended on histological confirmation, the sensitivity data are a reliable estimate of the yield from this localising technique. Despite the

obvious value of 123I-MIBG in confirming the nature of a radiological abnormality our

sensitivity data indicate the importance of additional cross-sectional imaging modalities in localising biochemically proven catecholamine-producing tumours.

Volume 6

194th Meeting of the Society for Endocrinology and Society for Endocrinology joint with Diabetes UK Endocrinology and Diabetes Day

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.